Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| ViiV Healthcare | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the affect that PF-00232798 has on QT interval. A prolonged QT interval is a risk factor for arrhythmias.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PF-00232798 supratherapeutic dose | Experimental | PF-00232798 supratherapeutic dose |
|
| PF-00232798 therapeutic dose | Experimental | PF-00232798 therapeutic dose |
|
| Placebo for PF-00232798 | Placebo Comparator | Placebo for PF-00232798 |
|
| Moxifloxacin | Active Comparator | Moxifloxacin |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PF-00232798 | Drug | 600 mg oral solution once daily x 7 days |
| |
| Measure | Description | Time Frame |
|---|---|---|
| QTc, using Fridericia's correction method (QTcF) at each time point of PF-00232798 and placebo on Day 7. | 7 days |
| Measure | Description | Time Frame |
|---|---|---|
| QTcF, or any other appropriate correction method at each postdose time point of moxifloxacin on Day 7 | 7 days | |
| QTcB or any other appropriate correction method at each postdose time point of PF-00232798 and placebo on Day 7 | 7 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | Singapore | 188770 | Singapore |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| C530956 | PF 232798 |
| D000077266 | Moxifloxacin |
| ID | Term |
|---|---|
| D024841 | Fluoroquinolones |
| D042462 | 4-Quinolones |
| D015363 | Quinolones |
| D011804 | Quinolines |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| PF-00232798 |
| Drug |
300 mg oral solution once daily x 7 days |
|
| Placebo | Drug | Oral solution once daily x 7 days |
|
| Moxifloxacin | Drug | 400 mg tablet single dose |
|
| Pharmacokinetic endpoints for PF-00232798 (Tmax, Cmax, Cτ, and AUClast) | 7 days |
| Safety and toleration assessed by spontaneous reporting of adverse events, vital signs, 12-lead ECG and laboratory safety assessments | 7 days |
| D006574 |
| Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |